Managed Healthcare Executive18h
Right Heart Size Should be Part of PAH Risk Models, Study Suggests
Women are more likely to have pulmonary arterial hypertension, but men tend to have worse outcomes and worse treatment responses.
Pulmonaryhypertensionnews.com4d
TX45 improves heart function, blood flow in PH-HFpEF
Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...
Healio4d
Winrevair PAH trial stopped due to earlier ‘robust evidence’
The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...
Joplin Globe8d
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis ...
Pulmonaryhypertensionnews.com9d
Right heart size differs between men and women with PAH: Study
Men with PAH had a larger right heart size and worse survival than women, independent of body size and functional status, a ...